Podocyte ageing and Fabry’s disease

The worldwide demographic increase in the elderly population will become a major health concern for modern societies in the future. Aging-related chronic kidney disease is a common problem of aged individuals, presenting with mild to severe impairment of kidney function. Yet, models to study renal aging are currently lacking. In order to identify molecular mechanisms involved in glomerular and kidney aging we analyze gene expression profiles, protein profiles and lipid profiles of young and aged kidney tissue. The aim of our research project is to identify molecules and pathways involved in the process of kidney aging to develop novel prevention strategies of age-related kidney function decline and therapies for healthy aging.

 
 
 

Fabry disease results from an inborn error of glycosphingolipid metabolism. Due to a mutation in the GLA gene on the X-chromosome activity of the lysosomal enzyme alpha galactosidase A (alpha-gal) is reduced or totally abolished. Neutral glycosphingolipids, mainly globotriaosylceramide (Gb3), accumulate in various tissues, including the kidneys. End-stage renal disease is one of the most common causes of death in hemizygous males with Fabry disease. The mechanism underlying proteinuria, hematuria, and kidney failure is not well understood. Histological studies suggest an important role for podocytes in the pathogenesis of glomerular damage. We developed a human podocyte model of Fabry’s disease by reducing alpha-gal activity in human podocytes, leading to progressive accumulation of intracellular Gb3. Interestingly, these changes are accompanied by a loss of mTOR kinase activity, a negative regulator of the autophagic machinery. Thus, dysregulated autophagy in alpha galactosidase A-deficient podocytes may contribute to podocyte malfunction in Fabry disease. Our research provides a promising new direction for further studies on the pathomechanism of glomerular injury in Fabry patients.

Group leader

Prof. Dr. med. Christine Kurschat 

Teammembers

  • Fabian Braun, MD

 

Selected publications

  1. Braun, F., Rinschen, M.M., Bartels, V., Frommolt, P., Habermann, B., Hoeijmakers, J.H., Schumacher, B., Dolle, M.E., Muller, R.U., Benzing, T., Schermer, B., and Kurschat, C.E. (2016). Altered lipid metabolism in the aging kidney identified by three layered omic analysis. Aging (Albany NY). 8(3):441-57.
  2. Ising, C., Koehler, S., Brahler, S., Merkwirth, C., Hohne, M., Baris, O. R., Hagmann, H., Kann, M., Fabretti, F., Dafinger, C., Bloch, W., Schermer, B., Linkermann, A., Bruning, J. C., Kurschat, C. E., Muller, R. U., Wiesner, R. J., Langer, T., Benzing, T., Brinkkoetter, P. T. (2015) Inhibition of insulin/IGF-1 receptor signaling protects from mitochondria-mediated kidney failure. EMBO Mol Med. 7(3):275-87.
  3. Schermer, B., Bartels, V., Frommolt, P., Habermann, B., Braun, F., Schultze, J. L., Roodbergen, M., Hoeijmakers, J. H., Schumacher, B., Nurnberg, P., Dolle, M. E., Benzing, T., Muller, R. U., Kurschat, C. E. (2013) Transcriptional profiling reveals progeroid Ercc1(-/Delta) mice as a model system for glomerular aging. BMC Genomics 14:559.
  4. Liebau, M. C., Braun, F., Hopker, K., Weitbrecht, C., Bartels, V., Muller, R. U., Brodesser, S., Saleem, M. A., Benzing, T., Schermer, B., Cybulla, M., Kurschat, C. E. (2013) Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PLoS One 8:e63506.
  5. Knebelmann, B., Kurschat, C., Thadhani, R. (2009) Enzyme therapy for Fabry's disease: registered for success? Lancet 374:1950-1951.